We have located links that may give you full text access.
JOURNAL ARTICLE
META-ANALYSIS
Atherosclerotic coronary plaque regression and the risk of adverse cardiovascular events: a meta-regression of randomized clinical trials.
Atherosclerosis 2013 January
INTRODUCTION: Atherosclerotic coronary plaques represent the main substrate for coronary artery disease (CAD), and changes in plaque volume, investigated with intravascular ultrasound (IVUS), have been used as surrogate end-points in several clinical trials. However, no conclusive data are available to support the exploitation of IVUS-based plaque changes as a measure of clinically meaningful treatment's effect.
METHODS: Biomed Central, CENTRAL, and Medline/PubMed were searched for randomized clinical trials investigating IVUS variations of plaque and reporting clinical events. End-points of interest were major adverse cardiovascular events (MACE, a composite of death, myocardial infarction [MI] or revascularization), and the rates of MI or revascularization combined. Meta-regression analysis was performed to appraise the association between plaque changes and clinical events during follow-up.
RESULTS: Eleven studies (2 focusing on patients with ACS) with 7864 patients were included. After a median follow-up of 18 months, percentage of atheroma volume (PAV) was 0.50 (95% confidence interval -0.25; 1.00), with a 15.0% (95% CI 9.6%; 22.5%) rate of MACE and a 14.1% (95% CI 10.2%; 19.5%) rate of MI or revascularization. Rates of plaque volume regression were significantly associated with the incidence of MI or revascularization (Beta = 6.3; p = 0.006) but not with MACE (Beta = 0.42; p = 0.208).
CONCLUSION: Regression of atherosclerotic coronary plaque volume may represent a surrogate for myocardial infarction and repeat revascularization but not for MACE. These results derive largely from stable patients, and should consequently be applied only to this population.
METHODS: Biomed Central, CENTRAL, and Medline/PubMed were searched for randomized clinical trials investigating IVUS variations of plaque and reporting clinical events. End-points of interest were major adverse cardiovascular events (MACE, a composite of death, myocardial infarction [MI] or revascularization), and the rates of MI or revascularization combined. Meta-regression analysis was performed to appraise the association between plaque changes and clinical events during follow-up.
RESULTS: Eleven studies (2 focusing on patients with ACS) with 7864 patients were included. After a median follow-up of 18 months, percentage of atheroma volume (PAV) was 0.50 (95% confidence interval -0.25; 1.00), with a 15.0% (95% CI 9.6%; 22.5%) rate of MACE and a 14.1% (95% CI 10.2%; 19.5%) rate of MI or revascularization. Rates of plaque volume regression were significantly associated with the incidence of MI or revascularization (Beta = 6.3; p = 0.006) but not with MACE (Beta = 0.42; p = 0.208).
CONCLUSION: Regression of atherosclerotic coronary plaque volume may represent a surrogate for myocardial infarction and repeat revascularization but not for MACE. These results derive largely from stable patients, and should consequently be applied only to this population.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app